Mesoblast Limited

NasdaqGS:MESO Stock Report

Market Cap: US$2.1b

Mesoblast Management

Management criteria checks 3/4

Mesoblast's CEO is Silviu Itescu, appointed in Jan 2004, has a tenure of 20.92 years. total yearly compensation is $2.02M, comprised of 25% salary and 75% bonuses, including company stock and options. directly owns 6.92% of the company’s shares, worth $142.45M. The average tenure of the management team and the board of directors is 5.2 years and 7.3 years respectively.

Key information

Silviu Itescu

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage25.0%
CEO tenure20.9yrs
CEO ownership6.9%
Management average tenure5.2yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Mesoblast Finally Gets Its Approval In GVHD: Where Now?

Dec 19

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Sep 30

Mesoblast: Rolling The Dice On Cellular Medicines

Jul 22

Mesoblast Limited: Back From The Dead

Apr 10

Mesoblast GAAP EPS of -$0.14, revenue of $10.21M

Aug 31

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Apr 30

Mesoblast issues FQ2 operational and financial update

Jan 29

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Jan 11

Mesoblast: The Future Looks Bleak

Dec 24

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Dec 15

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Dec 02

Mesoblast EPS beats by $0.22, misses on revenue

Nov 19

CEO Compensation Analysis

How has Silviu Itescu's remuneration changed compared to Mesoblast's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024US$2mUS$505k

-US$88m

Mar 31 2024n/an/a

-US$82m

Dec 31 2023n/an/a

-US$73m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023US$1mUS$673k

-US$82m

Mar 31 2023n/an/a

-US$81m

Dec 31 2022n/an/a

-US$84m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022US$1mUS$697k

-US$91m

Mar 31 2022n/an/a

-US$92m

Dec 31 2021n/an/a

-US$97m

Sep 30 2021n/an/a

-US$97m

Jun 30 2021US$2mUS$757k

-US$99m

Mar 31 2021n/an/a

-US$109m

Dec 31 2020n/an/a

-US$98m

Sep 30 2020n/an/a

-US$97m

Jun 30 2020US$2mUS$697k

-US$78m

Mar 31 2020n/an/a

-US$66m

Dec 31 2019n/an/a

-US$76m

Sep 30 2019n/an/a

-US$76m

Jun 30 2019US$1mUS$709k

-US$90m

Mar 31 2019n/an/a

-US$90m

Dec 31 2018n/an/a

-US$86m

Sep 30 2018n/an/a

-US$48m

Jun 30 2018US$2mUS$748k

-US$35m

Compensation vs Market: Silviu's total compensation ($USD2.02M) is below average for companies of similar size in the US market ($USD5.50M).

Compensation vs Earnings: Silviu's compensation has increased whilst the company is unprofitable.

CEO

Silviu Itescu (67 yo)

20.9yrs

Tenure

US$2,017,166

Compensation

Dr. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesoblast...

Leadership Team

NamePositionTenureCompensationOwnership
Silviu Itescu
Founder20.9yrsUS$2.02m6.92%
$ 142.4m
Eric Rose
Chief Medical Officer & Executive Director2.8yrsUS$1.53m0.51%
$ 10.6m
Andrew Chaponnel
Interim Chief Finance Officer3.3yrsno datano data
Peter Howard
General Counsel & Corporate Executive13.4yrsno datano data
Paul Simmons
Scientific Advisor to the Chief Executive Officer13.9yrsno datano data
Geraldine Storton
Head of Regulatory Affairs & Quality Managementno datano datano data
Justin Horst
Head of Manufacturingno datano datano data
Fiona See
Senior VP & Head of Translational Researchno datano datano data
Marcelo Santoro
Chief Commercial Officerno datano datano data
Niva Sivakumar
Joint Company Secretary5.2yrsno datano data
Paul Hughes
Joint Company Secretary2.7yrsno datano data
Kenneth Borow
Executiveno datano datano data

5.2yrs

Average Tenure

67yo

Average Age

Experienced Management: MESO's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Silviu Itescu
Founder17.5yrsUS$2.02m6.92%
$ 142.4m
Eric Rose
Chief Medical Officer & Executive Director11.7yrsUS$1.53m0.51%
$ 10.6m
Philip Facchina
Independent Non-Executive Director3.8yrsUS$112.47k0.011%
$ 222.4k
William A. Burns
Independent Non-Executive Vice Chairman10.8yrsUS$134.05k0.0093%
$ 191.7k
Henry Krum
Member of Scientific Advisory Boardno datano datano data
Joseph Lane
Member of Scientific Advisory Boardno datano datano data
Robert Graham
Member of Scientific Advisory Boardno datano datano data
Jane Bell
Independent Non-Executive Chairman2.3yrsUS$153.70k0.048%
$ 980.4k
Richard Gilbert
Member of Scientific Advisory Boardno datano datano data
Stephen Graves
Member of Scientific Advisory Boardno datano datano data
Philip Krause
Non-Independent Non Executive Director2.8yrsUS$343.70k0.025%
$ 518.6k

7.3yrs

Average Tenure

70yo

Average Age

Experienced Board: MESO's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 10:12
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mesoblast Limited is covered by 24 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter